Suzhou Innovent Bio in-licensed China rights to a novel treatment for type 2 diabetes from Eli Lilly. In 2015, Innovent and Lilly established a $1 billion collaboration to co-develop several Innovent cancer therapeutics, including its China-approved PD-1 drug, Tyvyt®. The Lilly diabetes candidate, an oxyntomodulin analog known as OXM3, is a dual GLP-1 and glucagon receptor agonist. Lilly believes the drug also causes significant weight loss. The two companies plan to develop OXM3 as a therapy for diabetes, obesity and potentially nonalcoholic steatohepatitis (NASH). Source: China Biotoday
